Platelet membrane proteins involved in aggregation

Platelet membrane proteins involved in aggregation are a diverse group of cell surface receptors and glycoproteins that mediate the complex process of platelet activation and thrombus formation. The most prominent member is the Integrin alpha-IIb/beta-3 (GPIIb/IIIa) complex, which acts as the final common pathway for aggregation by binding fibrinogen and von Willebrand factor to cross-link adjacent platelets (Source: StatPearls, Physiology, Platelet). Other critical proteins include the P2Y12 and P2Y1 receptors, which respond to adenosine diphosphate (ADP), and the protease-activated receptors (PAR1 and PAR4), which are triggered by thrombin (Source: PubMed, PMID: 28838933). The Glycoprotein Ib-IX-V complex is also essential for the initial tethering of platelets to the damaged vessel wall via von Willebrand factor (Source: UniProt, P07359). These proteins are major therapeutic targets for antiplatelet therapy to prevent and treat arterial thrombosis, including myocardial infarction and ischemic stroke (Source: NIH, Antiplatelet Medications). Drugs targeting these proteins, such as P2Y12 inhibitors (e.g., clopidogrel) and GPIIb/IIIa antagonists (e.g., abciximab), significantly reduce cardiovascular events but are associated with an increased risk of bleeding (Source: FDA, Plavix Prescribing Information).

Other names

Platelet surface receptorsPlatelet glycoproteinsThrombocyte membrane proteinsPlatelet aggregation receptors

Inhibition of ADP-induced platelet activation via P2Y12 receptor antagonism; blockade of fibrinogen binding to the Integrin alpha-IIb/beta-3 complex; and inhibition of thrombin-induced activation via PAR1 antagonism.